Publications

(Displaying in Reverse Chronological Order)

  1. Research
  2. Publications
  3. Publications
2296
Singh S, Mariappan TT and Bhutani H. Novel anti-TB FDC formulations without reduced bioavailability of rifampicin: from concept to market International Journal of Tuberculosis and Lung Disease 2005, 9, 701-702.
2297
Sobhia ME and Bharatam PV. Comparative molecular similarity indices analysis (CoMSIA) studies of 1,2-naphthoquinone derivatives as PTP1B inhibitors Bioorganic & Medicinal Chemistry 2005, 13, 2331-2338.
2298
Soni P and Banerjee UC. Biotransformations for the production of the chiral drug (S)-Duloxetine catalyzed by a novel isolate of Candida tropicalis Applied Microbiology and Biotechnology 2005, 67, 771-777.
2299
Soni P, Banerjee UC and Mariappan TT. High-performance liquid chromatographic method for the simultaneous estimation of the key intermediates of duloxetine Talanta 2005, 67, 975-978.
2300
Soni P, Banerjee UC, Kaur G and Chakraborti AK. Candida viswanathii as a novel biocatalyst for stereoselective reduction of heteroaryl methyl ketones: A highly efficient enantioselective synthesis of (S)-α-(3-pyridyl)ethanol Tetrahedron Asymmetry 2005, 16, 2425-2428.
2301
Sonkusare S, Srinivasan K, Kaul CL and Ramarao P. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats Life Sciences 2005, 77, 14-1.
2302
Srikanth CV, Chakraborti AK, Bachhawat AK. Acetaminophen Toxicity and Resistance in the Yeast Saccharomyces Cerevisiae Microbiology 2005, 151, 99-111.
2303
Srinivasan K, Kaul CL and Ramarao P. Partial protective effect of rutin on multiple low dose streptozotocin-induced diabetes in mice [2] Indian Journal of Pharmacology 2005, 37, 327-328.
2304
Srinivasan K, Viswanad B, Asrat L, Kaul CL and Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening Pharmacological Research 2005, 52, 313-320.
2305
Tamta H, Thilagavathi R, Chakraborti AK and Mukhopadhyay AK. 6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: inhibition mechanism and molecular modeling studies Journal of Enzyme Inhibition and Medicinal Chemistry 2005, 20, 317-324.
2306
Thilagavathi R, Kumar R, Aparna V, Sobhia ME, Gopalakrishnan B and Chakraborti AK. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA) Bioorganic & Medicinal Chemistry Letters 2005, 15, 1027-1032.
2307
Varma MV and Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo European Journal of Pharmaceutical Sciences 2005, 25, 445-453.
2308
Varma MV and Panchagnula R. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ Journal of Pharmaceutical Sciences 2005, 94, 2632-2643.
2309
Varma MV and Panchagnula R. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability Journal of Pharmaceutical Sciences 2005, 94, 1694-1704.
2310
Varma MV, Kaushal AM and Garg S. Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices Journal of Controlled Release 2005, 103, 499-510.
2311
Varma MV, Khandavilli S and Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport Molecular Pharmaceutics 2005, 2, 21-12.
2312
Varma MV, Sarkar M, Kapoor N and Panchagnula R. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1 Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2005, 816, 243-249.
2313
Vats P and Banerjee UC. Biochemical characterisation of extracellular phytase (myo-inositol hexakisphosphate phosphohydrolase) from a hyper-producing strain of Aspergillus niger van Teighem Journal of Industrial Microbiology and Biotechnology 2005, 32, 141-147.
2314
Verma RK and Garg S. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing Journal of Pharmaceutical and Biomedical Analysis 2005, 38, 633-644.
2315
Visalakshi NA, Mariappan TT, Bhutani H and Singh S. Behavior of moisture gain and equilibrium moisture contents (EMC) of various drug substances and correlation with compendial information on hygroscopicity and loss on drying Pharmaceutical Development and Technology 2005, 10, 489-497.
2316
Wadhwa LK, Ravikumar K, Saxena R, Singh S and Swamy GYSK. (2R*,3R*,6S*)-N,6-Bis(4-fluorophenyl)-2-(4-hydroxyphenyl)-3,4,5,6-tetrahydro-2H-pyran-3-carboxamide Acta Crystallographica Section E 2005, E61, o3608-o3610..
2317
Aboye TL, Sobhia ME and Bharatam PV. 3D-QSAR studies of pyruvate dehydrogenase kinase inhibitors based on a divide and conquer strategy Bioorganic & Medicinal Chemistry 2004, 12, 2709-2715.
2318
Agrawal S and Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations International Journal of Pharmaceutics 2004, 287, 97-112.
2319
Agrawal S and Panchagnula R. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms Die Pharmazie 2004, 59, 775-785.
2320
Agrawal S and Panchagnula R. In vitro evaluation of fixed dose combination tablets of anti-tuberculosis drugs after real time storage at ambient conditions Die Pharmazie 2004, 59, 782-785.
2321
Agrawal S, Ashokraj Y, Bharatam PV, Pillai PO and Panchagnula R. Solid-state characterization of rifampicin samples and its Biopharmaceutic relevance European Journal of Pharmaceutical Sciences 2004, 22, 127-144.
2322
Agrawal S, Singh I, Kaur KJ, Bhade S, Kaul CL and Panchagnula R. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin Pharmacological Research 2004, 50, 317-327.
2323
Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL and Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels International Journal of Pharmaceutics 2004, 276, 41-49.
2324
Arun KHS, Kaul CL and Ramarao P. High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta Pharmacological Research 2004, 50, 561-568.
2325
Arun KHS, Kaul CL and Ramarao P. Tempol augments angiotensin II induced AT2-receptor mediated relaxation in diabetic rat thoracic aorta Journal of Hypertension 2004, 22, 2143-2152.
2326
Ashokraj Y, Agrawal S, Varma MVS, Singh I, Gunjan K, Kaur KJ, Bhade SR, Kaul CL, Caudron JM, Pinel J and Panchagnula R. Quality control of anti-tuberculosis fixed dose combination formulations in global market: An in vitro study International Journal of Tuberculosis and Lung Disease 2004, 8, 1081-1088.
2327
Babu MA, Sobhia ME, Sharma M, Khanna S, Bharatam PV and Kaskhedikar SG. 3D-QSAR CoMFA CoMSIA studies on indomethacin derivatives as selective cyclooxygenase-2 inhibitors Indian Journal of Pharmaceutical Sciences 2004, 66, 613-620.
2328
Bakshi M and Singh S. HPLC and LC-MS studies on stress degradation behaviour of tinidazole and development of a validated specific stability-indicating HPLC assay method Journal of Pharmaceutical and Biomedical Analysis 2004, 34, 18-11.
2329
Bakshi M and Singh S. ICH guidance in practice: Establishment of inherent stability of secnidazole and development of a validated stability-indicating high performance liquid chromatographic assay method Journal of Pharmaceutical and Biomedical Analysis 2004, 36, 769-775.
2330
Bakshi M, Ojha T and Singh S. Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions Journal of Pharmaceutical and Biomedical Analysis 2004, 34, 19-26.
2331
Banga S, Chawla G and Bansal AK. New trends in crystallization of active pharmaceutical ingredients, business and briefing Business briefings: Pharmacogenerics 2004, .
2332
Bharatam PV. Rapid Racemization in Thiazolidinediones: A Quantum Chemical Study Journal of Physical Chemistry. A 2004, 108, 3784-3788.
2333
Bharatam PV, Amita S and Senthilkumar P. Theoretical investigations on R(O)nS-NO (n=0,1,2) systems Tetrahedron 2004, 60, 4801-4805.
2334
Bharatam PV, Iqbal P, Malde A and Tiwari R. Electron delocalisation in aminoguanidine: A computational study Journal of Physical Chemistry. A 2004, 108, 10509-10517.
2335
Bhutani H, Mariappan TT and Singh S. An Explanation for the Physical Instability of a Marketed Fixed Dose Combination (FDC) Formulation Containing Isoniazid and Ethambutol and Proposed Solutions Drug Development and Industrial Pharmacy 2004, 30, 667-672.
2336
Bhutani H, Mariappan TT and Singh S. The Physical and Chemical Stability of Marketed Anti-Tubercular Fixed Dose Combination (FDC) Products under Accelerated Climatic Conditions International Journal of Tuberculosis and Lung Disease 2004, 8, 1073-1080.
2337
Bhutani KK, Jadhav AN and Kalia V. Effect of Symplocos racemosa Roxb on gonadotropin release in immature female rats and ovarian histology Journal of Ethnopharmacology 2004, 94, 197-200.
2338
Chakraborti AK and Gulhane R. Zirconium (IV) chloride as a new, highly efficient, and reusable catalyst for acylation of phenols, thiols, amines, and alcohols under solvent free conditions Synlett 2004, 2004, 627-630.
2339
Chakraborti AK and Thilagavathi R. Computer-aided design of selective COX-2 inhibitors: Molecular docking of structurally diverse COX-2 inhibitors using Flex-X method Internet Electronic Journal of Molecular Design 2004, 3, 704-719.
2340
Chakraborti AK, Bhagat S and Rudrawar S. Magnesium perchlorate as an efficient catalyst for synthesis of imines and phenylhydrazones Tetrahedron Letters 2004, 45, 7641-7644.

Information: Duration to be uploaded/incorporated on archival site after the completion of process is 12 months.

2627|52|45